Immuneering Corporation to present at Oppenheimer Healthcare Conference, discussing its cancer therapies and development pipeline.
Quiver AI Summary
Immuneering Corporation, a clinical-stage oncology company focused on developing improved cancer therapies, announced that its management, including CEO Ben Zeskind and Chief Scientific Officer Brett Hall, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually from February 11-12, 2025. They will discuss the company's therapeutic pipeline and business strategy, with their presentation scheduled for February 12 from 2:40 to 3:10 pm ET. The event will be accessible through a live webcast and subsequently archived on Immuneering's website. The company is developing its lead product candidate, IMM-1-104, aimed at treating RAS-driven tumors, currently undergoing clinical trials along with another candidate, IMM-6-415. For more details, visit their website.
Potential Positives
- The presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference highlights the company's commitment to transparency and engagement with investors and stakeholders.
- Immuneering is advancing its lead product candidate, IMM-1-104, into clinical trials, showcasing progress in developing therapies for difficult-to-treat cancers, such as pancreatic cancer.
- The company is actively pursuing multiple product candidates, including IMM-6-415, indicating a robust and diversifying pipeline which could lead to potential new therapies.
Potential Negatives
- Management's need to present at a healthcare conference indicates potential challenges in gaining investor confidence in their pipeline and strategy, suggesting they may not be meeting market expectations.
- The focus on early-stage programs and ongoing trials may highlight a lack of advanced products nearing commercialization, which could be a concern for potential investors looking for more immediate returns.
- The mention of RAS-driven tumors and pancreatic cancer, which are highly challenging areas in oncology, may underscore the difficulties the company faces in achieving successful outcomes in their clinical trials.
FAQ
What is Immuneering Corporation?
Immuneering Corporation is a clinical-stage oncology company focused on developing effective and better tolerated cancer therapies.
When is Immuneering's presentation at the Oppenheimer Conference?
Immuneering will present on February 12, 2025, from 2:40 – 3:10 pm ET.
Who will represent Immuneering at the conference?
Ben Zeskind, CEO, and Brett Hall, Chief Scientific Officer, will represent Immuneering at the conference.
How can I watch the Immuneering presentation?
The presentation will be webcast live and archived on Immuneering’s website in the Investor Relations section.
What is the lead product candidate of Immuneering?
Immuneering's lead product candidate is IMM-1-104, an oral MEK inhibitor aimed at treating RAS-driven tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMRX Hedge Fund Activity
We have seen 12 institutional investors add shares of $IMRX stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 1,882,136 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $4,686,518
- GOLDMAN SACHS GROUP INC removed 741,548 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,846,454
- MILLENNIUM MANAGEMENT LLC removed 706,956 shares (-74.2%) from their portfolio in Q3 2024, for an estimated $1,760,320
- MORGAN STANLEY added 403,259 shares (+875.7%) to their portfolio in Q3 2024, for an estimated $1,004,114
- MARSHALL WACE, LLP removed 384,075 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $956,346
- PROSIGHT MANAGEMENT, LP removed 360,000 shares (-65.5%) from their portfolio in Q3 2024, for an estimated $896,400
- RENAISSANCE TECHNOLOGIES LLC removed 349,100 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $869,259
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.
Format: Company Presentation and 1x1 Investor Meetings
Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2
The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation .
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com .
Media Contact:
Gina Nugent
[email protected]
Investor Contact:
Laurence Watts
619-916-7620
[email protected]